Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A1 | P18405 | 3/20 | 0.48 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.48 |
| ▸ | ABL1 | P00519 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.42 |
| ▸ | SLC6A15 | Q9H2J7 | 2/20 | 0.41 |
| ▸ | HSD17B3 | P37058 | 2/20 | 0.40 |
| ▸ | ALPL | P05186 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | FNTA | P49354 | 1/20 | 0.38 |
| ▸ | FNTB | P49356 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL588072 | 0.82 | MAPK14 (0.43) | SRD5A1SLC6A3ALPLKDM4EGLA | |
| SCHEMBL588713 | 0.82 | RAB9A (0.58) | ALPLKDM4EGLAGAAMAPT | |
| SCHEMBL4025662 | 0.81 | SRD5A1 (0.61) | SRD5A1SRD5A2HTTSLC6A15FNTA | |
| SCHEMBL9448045 | 0.73 | SRD5A1 (0.44) | SRD5A1SRD5A2ABL1HTTSLC6A3 | |
| SCHEMBL6648373 | 0.73 | L3MBTL1 (0.42) | SRD5A1SRD5A2SLC6A3HSD17B3KDM4E | |
| SCHEMBL12447830 | 0.73 | SLC6A3 (0.44) | SRD5A1SRD5A2ABL1SLC6A3HSD17B3 | |
| SCHEMBL23058960 | 0.72 | MAPK14 (0.58) | SRD5A1SRD5A2HSD17B3 | |
| SCHEMBL21474580 | 0.71 | SLC6A3 (0.44) | SRD5A1SRD5A2ABL1SLC6A3HSD17B3 | |
| SCHEMBL6100118 | 0.70 | ABL1 (0.70) | ABL1HTTSLC6A3ALPLKDM4E | |
| SCHEMBL15282381 | 0.69 | SRD5A1 (0.64) | SRD5A1SRD5A2HTTSLC6A3SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8258168-B2 | 2H or 3H-benzo[E]indazol-1-YL carbamate derivatives, the preparation and therapeutic use thereof | SANOFI (FR) | 2012-09-04 | — | — | US | disclosed |
| US-20120108584-A1 | 2H OR 3H-BENZO[E]INDAZOL-1-YL CARBAMATE DERIVATIVES, THE PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2012-05-03 | — | — | US | disclosed |
| US-8114899-B2 | 2H- or 3H-benzo[e]indazol-1-yl carbamate derivatives, the preparation and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2012-02-14 | — | — | US | disclosed |
| US-20090143380-A1 | 2H- OR 3H-BENZO[E]INDAZOL-1-YL CARBAMATE DERIVATIVES, THE PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2009-06-04 | — | — | US | disclosed |
| US-7501449-B2 | 2H -or 3H-benzo[e]indazol-1-yl carbamate derivatives, the preparation and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2009-03-10 | — | — | US | disclosed |
| US-20070105932-A1 | 2H-or 3H-benzo[e]indazol-1-yl carbamate derivatives, the preparation and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105932-A1 | 2H-or 3H-benzo[e]indazol-1-yl carbamate derivatives, the preparation and therapeutic use thereof | GLS2, GLS, CYP11B2 | SRD5A1 1162/4885SRD5A2 925/4885ABL1 45/4885 |
| US-20090143380-A1 | 2H- OR 3H-BENZO[E]INDAZOL-1-YL CARBAMATE DERIVATIVES, THE PREPARATION AND THERAPEUTIC USE THEREOF | GLS2, GLS, SDHA | SRD5A1 1025/4885SRD5A2 804/4885ABL1 65/4885 |
| US-20120108584-A1 | 2H OR 3H-BENZO[E]INDAZOL-1-YL CARBAMATE DERIVATIVES, THE PREPARATION AND THERAPEUTIC USE THEREOF | GLS2, GLS, SDHA | SRD5A1 1244/4885SRD5A2 1008/4885ABL1 96/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.